Ara
Toplam kayıt 6, listelenen: 1-6
Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
(Elsevier Science Inc, 2018)
Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We ...
Prognostic significance of positive lymph node ratio in patients with pN3 gastric cancer who underwent curative gastrectomy
(Oxford University Press, 2017)
Introduction: Lymph node metastasis is an important prognostic factor for patients with gastric cancer. The aim of this study was to determine the prognostic significance of metastatic lymph node ratio (MLNR) in pN3 gastric ...
Prognostic factors in patients with metastatic urothelial carcinoma who have been treated with atezolizumab
(Elsevier, 2020)
Background: In the current study, we evaluated pretreatment prognostic factors foroverall survival (OS) in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy in the Expanded-Access ...
The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey Molecular Profiling in Advanced Cancers Trial (TUMPACT)
(Elsevier, 2020)
Background: Molecular genetic profiling (MGP) which has started to take an important part in cancer diagnosis and treatment in recent years, has entered the routineclinical practice much faster than expected. We aimed to ...
Are pretreatment inflammation-based prognostic scores useful in predicting the outcomes of patients with ALK-positive NSCLC?
(Elsevier Science, 2019)
Background: Approximately 5% of all diagnosed non-small cell lung cancer (NSCLC) patients harbor a genetic rearrangement between the ALK and EML4 genes, representing a specific molecular and clinical subgroup (ALK+ NSCLC). ...
Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
(Elsevier Science, 2019)
Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK ...